News

• Aclarion Announces Pricing of $3.0 Million Public Offering

  February 26, 2024

• Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

  February 5, 2024

• Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

  January 22, 2024

• Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution

  January 17, 2024

• Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan

  January 8, 2024

• Aclarion Announces Reverse Stock Split

  January 2, 2024

• Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

  November 27, 2023

• Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption

  November 8, 2023

• Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

  November 6, 2023

• Aclarion Presents at the NIH HEAL Initiative Fall Meeting

  November 1, 2023